What is LiteCure?
LiteCure is at the forefront of therapeutic laser technology, focusing on photobiomodulation to accelerate healing and recovery processes. The company offers a diverse product portfolio, including the LightForce Deep Tissue Laser Therapy for human medical applications, Companion Therapy Lasers for veterinary professionals, and Pegasus Therapy Lasers tailored for equine athletes. These solutions provide drug-free and surgery-free pain relief, catering to a global clientele seeking advanced, non-invasive treatment options. LiteCure's commitment to innovation positions it as a key player in the rapidly evolving field of therapeutic light-based treatments.
How much funding has LiteCure raised?
LiteCure has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in LiteCure
PPP
Public-Private Partnership
What's next for LiteCure?
With the recent major strategic investment, LiteCure is poised for significant growth and market expansion. The enterprise-level capital infusion is expected to fuel advancements in their photobiomodulation technology, potentially leading to new product development and enhanced therapeutic applications. This strategic backing will likely enable LiteCure to broaden its market penetration in both the medical and veterinary fields, solidifying its position as a leader in laser therapy solutions. The company's focus on drug-free and surgery-free pain relief aligns with a growing global demand for alternative and complementary healthcare modalities, suggesting a strong trajectory for future success and innovation.
See full LiteCure company page
